PPMX-T002 is under clinical development by Perseus Proteomics and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II drugs for Colorectal Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PPMX-T002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PPMX-T002 overview
PPMX-T002 (FF-21101) is under development for the treatment of solid tumors including pancreatic neuroendocrine tumor, ovarian cancer, liposarcoma, vaginal cancer, desmoplastic small round cell (DSRC) tumor epithelial ovarian cancer, peritoneal cancer, fallopian tube carcinoma, metastatic biliary tract cancer, triple negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), cholangiocarcinoma, pancreatic carcinoma and colorectal cancer. The drug is administered by injection. It is a radioimmunoconjugate consisting of a chimeric monoclonal antibody targeting human cadherin-3 (CDH3) and labeled, via the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), with the beta-emitting radioisotope yttrium Y 90.
It was also under development for the treatment of oral cavity (mouth) cancer, papillary tumor, maxillary sinusitis, oropharyngeal cancer, hypopharyngeal cancer, non-small cell lung cancer, islet cell carcinoma and laryngeal cancer.
For a complete picture of PPMX-T002’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - PPMX-T002 in Colorectal Cancer
Premium Insights
The gold standard of business intelligence.
